Allowable Commercialization Costs definition

Allowable Commercialization Costs has the meaning set forth in the Financial Definitions Exhibit.
Allowable Commercialization Costs means the internal costs (i.e. FTE Costs) and Out-of-Pocket Costs actually incurred by or on behalf of a Party or its Affiliates or Sublicensees, that are [***] including [***]: [***]
Allowable Commercialization Costs means the internal costs (i.e. FTE Costs) and Out-of-Pocket Costs actually incurred by or on behalf of a Party or its Affiliates or Sublicensees, that are [***] including [***]: [***] in each case (except in the case of [***] to the extent such costs are consistent with, during the Merck Participation Term for a given Joint SAV Program or the PCV Program, the Global Commercialization Plan and the Global Commercialization Budget for such Joint SAV Program or the PCV Program or otherwise approved by the JSC, plus Permitted Overages. [***]The Parties agree that Allowable Commercialization Costs will not include costs or expenses of a Party or its Affiliates or Sublicensees to the extent: [***]. No expense included in an Allowable Commercialization Cost shall also be included in other costs in the calculations of Moderna Net Profits or Cash Profits or Losses.

Examples of Allowable Commercialization Costs in a sentence

  • Each party shall contribute to Allowable Commercialization Costs as specified in Article 9.

  • Gross sales, Net Sales, Allowable Commercialization Costs and Operating Profit/Loss attributable to countries other than the United States shall be calculated in accordance with the standard exchange rates published in the Wall Street Journal (New York edition) and otherwise in accordance with the standard exchange rate conversion practices used by the reporting party for financial accounting purposes.

  • For clarity, Allowable Development Costs, Allowable Joint IP Costs and Allowable Commercialization Costs for each Calendar Quarter may include accruals/estimates, and those accruals/estimates will be trued up to actual costs each Calendar Quarter as part of the cost reporting for the following Calendar Quarter.

  • The Parties shall each keep accurate books and accounts of record in connection with the Commercialization of the Collaboration Product in a manner consistent with GAAP and in sufficient detail to permit accurate determination of all figures necessary for verification of gross sales, Net Sales, Allowable Commercialization Costs, Operating Profit/Loss and Details performed hereunder.

  • It is further intended that each party shall contribute to Allowable Commercialization Costs in proportion to the Cost and Revenue Sharing Ratio, and the Commercialization Plan(s) will be consistent with and provide for such proportional contribution.

  • The parties shall each keep accurate books and accounts of record in connection with the Commercialization of the Licensed Product in a manner consistent with GAAP and in sufficient detail to permit accurate determination of all figures necessary for verification of gross sales, Net Sales, Allowable Commercialization Costs, Operating Profit/Loss and Details performed hereunder.


More Definitions of Allowable Commercialization Costs

Allowable Commercialization Costs means, with respect to the Commercialization of the Licensed Product for the Territory in a given period, the sum of the following with respect to such Licensed Product in such period, but solely to the extent (a) incurred by a Party (or its Affiliate) on or after the Effective Date as a cost or expense in accordance with the applicable Party’s Accounting Standards, (b) directly attributable or reasonably allocable to the Commercialization of such Licensed Product for the Territory, including, for clarity, those that are directly attributable or reasonably allocable to the Commercialization of a Proprietary Combination pursuant to this Agreement and the Commercialization Plan (and, for clarity, costs associated with the Commercialization of a Proprietary Combination pursuant to this Agreement and the Commercialization Plan shall be fully allocated to the Licensed Product hereunder), including, for example, Promotional Materials for the Licensed Product that reference a Proprietary Combination (but excluding for clarity any Merck Proprietary Combination Outside Promotional Materials and SeaGen Proprietary Combination Outside Promotional Materials) and (c) within the scope of the activities set forth in the Commercialization Plan and in accordance with the Commercialization Budget (plus any Permitted Commercialization Overage): 1.5.1 [ * ]; 1.5.2 [ * ]; 1.5.3 [ * ]; provided that, (i) if SeaGen is [ * ], this Section 1.5.3 shall exclude [ * ], but shall include [ * ] and (ii) if Merck is [ * ], this Section 1.5.3 shall exclude [ * ], but shall include [ * ]; 1.5.4 such costs and expenses incurred [ * ]; 1.5.5 [ * ] payable as a result of [ * ]; and 1.5.6 [ * ] costs and expenses [ * ] incurred by or on behalf of [ * ] in carrying out [ * ]. -2- [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED
Allowable Commercialization Costs means the sum of the following (without any item being accounted for more than once): (a)
Allowable Commercialization Costs means ***.

Related to Allowable Commercialization Costs

  • Commercialization Costs means the sum of the following costs and expenses incurred by the Parties or their respective Affiliates, in Commercializing the Shared Products (and related Manufacturing activities) in the Territory, in each case, to the extent incurred in accordance with the Commercialization Plan and Commercialization Budget:

  • Development Costs means costs incurred to obtain access to reserves and to provide facilities for extracting, treating, gathering and storing the oil and gas from reserves. More specifically, development costs, including applicable operating costs of support equipment and facilities and other costs of development activities, are costs incurred to:

  • Development Expenses means, with respect to SAIL Developments as well as HOME Developments when the HOME Development is also at least partially financed with a MMRB Loan (as defined in rule Chapter 67-21, F.A.C.), usual and customary operating and financial costs, such as the compliance monitoring fee, the financial monitoring fee, replacement reserves, the servicing fee and the debt service reserves. As it relates to SAIL Developments as well as HOME Developments when the HOME Development is also at least partially financed with a MMRB Loan (as defined in rule Chapter 67-21, F.A.C.) and to the application of Development Cash Flow described in subsections 67-48.010(5) and (6), F.A.C., as it relates to SAIL Developments or in paragraph 67-48.020(3)(b), F.A.C., as it relates to HOME Developments, the term includes only those expenses disclosed in the operating pro forma on an annual basis included in the final credit underwriting report, as approved by the Board, and maximum of 20 percent Developer Fee per year.

  • Manufacturing Costs means the costs of Processing that generate Manufacturing Proceeds received by Grantor.

  • Development Activities means those activities which are normally undertaken for the development, construction, repair, renovation, rehabilitation or conversion of buildings for residential purposes, including the acquisition of property;

  • Allowable Costs means the costs defined as allowable in 42 CFR, Chapter IV, Part 413, as amended to October 1, 2007, except for the purposes of calculating direct medical education costs, where only the reported costs of the interns and residents are allowed. Further, costs are allowable only to the extent that they relate to patient care; are reasonable, ordinary, and necessary; and are not in excess of what a prudent and cost-conscious buyer would pay for the given service or item.

  • Development Cost means the total of all costs incurred in the completion of a Development excluding Developer Fee, operating deficit reserves, and total land cost as typically shown in the Development Cost line item on the development cost pro forma.

  • Development Budget shall have the meaning set forth in Section 3.3.

  • Research Budget has the meaning set forth in Section 3.2.

  • Commercialization or “Commercialize” means activities directed to marketing, promoting, research and development as required, manufacturing for sale, offering for sale, distributing, importing or selling a product, including sub-licensing or sub-contracting of these activities.

  • Patent Expenses means all reasonable costs (including attorneys’ and application fees) incurred by University in accordance with this Agreement to apply for, prosecute and maintain Licensed Patents, including but not limited to the costs of interferences, oppositions, inter partes review and re-examinations. Patent Expenses include reimbursement for in-house costs provided they are for activities that would otherwise have been performed by outside counsel at an equal or greater expense.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Manufacturing Cost means [***].

  • Marketing Costs which means such reasonable charge for marketing of ores and concentrates sold or of concentrates tolled as is consistent with generally accepted industry marketing practices;

  • Development Plan has the meaning set forth in Section 3.2.

  • Development Activity means any activity defined as Development which will necessitate a Floodplain Development Permit. This includes buildings, structures, and non-structural items, including (but not limited to) fill, bulkheads, piers, pools, docks, landings, ramps, and erosion control/stabilization measures.

  • Program Costs means all necessary and incidental costs of providing program services.

  • Marketing Expenses mean the sum of Marketing Management Expenses, Advertising and Market Research Expenses and Medical Education Expenses.

  • Development Plans has the meaning set forth in Section 3.2.

  • Manufacturing operation means a process in which materials are changed, converted, or transformed into a different state or form from which they previously existed and includes refining materials, assembling parts, and preparing raw materials and parts by mixing, measuring, blending, or otherwise committing such materials or parts to the manufacturing process. "Manufacturing operation" does not include packaging.

  • Development Phase means the period before a vehicle type is type approved.

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • Routine Patient Costs means all health care services that are otherwise covered under the Group Contract for the treatment of cancer or other Life-threatening Condition that is typically covered for a patient who is not enrolled in an Approved Clinical Trial.

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Allowable Expenses means any necessary, reasonable and customary item of expense at least a portion of which is covered under at least one of the Health Benefit Plans covering the person for whom claim is made. When a Health Benefit Plan provides benefits in the form of coverage for services, the reasonable cash value of each service rendered shall be deemed to be both an Allowable Expense and a benefit paid.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.